Table 4.
Association Between Eradication Status and Rate of Physician-Defined Pulmonary Exacerbations Requiring Intravenous Antibiotics or Hospitalization During the Follow-up Period
| Rate Ratio | 95% CI | P Value | |
|---|---|---|---|
| Exacerbation rate (unadjusted) | |||
| Nonsustained eradicator | … | … | … |
| Sustained eradicator | 0.86 | (.54–1.34) | .501 |
| Exacerbation rate (adjusted multivariable model) | |||
| Intercept | 0.16 | (.09–.28) | <.001 |
| Nonsustained eradicator | … | … | … |
| Sustained eradicator | 0.85 | (.53–1.35) | .492 |
| Sex | |||
| Male | … | … | … |
| Female | 1.82 | (1.19–2.80) | .005 |
| Age at trial completion | |||
| <6 y | … | … | … |
| 6 to <10 y | 1.28 | (.77–2.15) | .355 |
| ≥10 y | 1.29 | (.74–2.28) | .387 |
| Pa history prior to trial enrollment | |||
| No lifetime history of Pa positivity | … | … | … |
| Lifetime history of Pa positivity | 1.38 | (.86–2.22) | .206 |
| Treatment regimen received during the trial | |||
| Culture-based therapy | … | … | … |
| Cycled therapy | 1.37 | (.90–2.10) | .139 |
Abbreviations: CI, confidence interval; Pa, Pseudomonas aeruginosa.